Lineage Cell Therapeutics (LCTX) Operating Leases (2014 - 2026)

Lineage Cell Therapeutics' Operating Leases history runs 13 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• In Q1 2026, Operating Leases rose 48.77% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (up 48.77% YoY), while the FY2025 annual figure was $1.5 million, up 18.46% from the prior year.
• Operating Leases for Q1 2026 stood at $1.5 million, down from $1.5 million in the prior quarter.
• The five-year high for Operating Leases was $2.9 million in Q4 2022, with the low at $1.0 million in Q1 2025.
• The 5-year median for Operating Leases is $1.8 million (2024), against an average of $1.8 million.
• The sharpest annual moves came in 2023 and 2025: Operating Leases surged 57.92% in 2023, then plunged 51.16% in 2025.
• Lineage Cell Therapeutics' Operating Leases stood at $2.9 million in 2022, then sank by 30.8% to $2.0 million in 2023, then sank by 34.56% to $1.3 million in 2024, then grew by 18.46% to $1.5 million in 2025, then decreased by 1.76% to $1.5 million in 2026.
• Business Quant data shows LCTX's Operating Leases at $1.5 million in Q1 2026, $1.5 million in Q4 2025, and $1.5 million in Q3 2025.